Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular...
-
Upload
janel-roberts -
Category
Documents
-
view
218 -
download
0
Transcript of Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular...
![Page 1: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/1.jpg)
Molecular Testing of lung cancer in routine practice
Philippe Taniere
Histopathology/Molecular Pathology,
Queen Elizabeth Hospital, Birmingham
![Page 2: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/2.jpg)
Current situation
• EGFR mutation and ALK translocation testing within 3/5 working days at the time of diagnosis
• Challenges– Small specimens, including cytology specimens more
and more– Uncertainty on how to assess ALK (IHC/FISH)– ISO/Accreditation requirements; quality control
schemes
No commissioning system in place
![Page 3: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/3.jpg)
Challenges for the future
• EGFR, BRAF KRAS, PIK3CA, HER2 mutations• ALK, ROS, RET translocations• C-MET, HER2, FGFR1 amplifications• Secondary mutations within EGFR or ALK in patients
under targeted therapy• Monitoring level of mutations in blood for patients under
treatment• PDL1 expression• Tumour infiltrating lymphocytes• ERCC1 level of expression
![Page 4: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/4.jpg)
Molecular profiling of solid tumours in routine practice
Mutation testing in
tissue
Single target by real time PCR or pyrosequencing
Multiplex testing on NGS
Mutation testing in blood
Surrogate to tissue for diagnosis
Monitoring patients under
TKI
Microscope based tests
IHC
Molecular: ALK, MET, PDL1
Multiplex (TILs)
FISH
![Page 5: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/5.jpg)
Molecular Pathology NHS Diagnostic Laboratory
• Multiplex testing–More than one–Less than too many
![Page 6: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/6.jpg)
Clinical relevance
• Diagnostic • Prognostic • Predictive
–Targeted drugs–Non targeted drugs
![Page 7: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/7.jpg)
Clinical relevance
• How do we decide what tests will be part of our panel?
Evidence based• Licensing• Trials• Research papers
![Page 8: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/8.jpg)
Multiplex testingA single panel on next generation sequencing
• Advantages:– Extensive tumour profiling upfront to guide treatment– Choice of therapy if several actionable mutations
• Pitfalls– No consensus on number of genes– DNA “hungry” technology: not suitable for at least
30% of real life specimens– Over two weeks turn around time– Not accredited technology– Complex reports
![Page 9: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/9.jpg)
Next Generation Sequencing
![Page 10: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/10.jpg)
NGS in practice
• Development of clinically relevant panels– SMP2 panel which includes ALK, ROS, RET: lung
specific; trials mainly (Illumina) (50 ng DNA)– Qiagen commercial panels– Illumina commercial panels– OGT– Roche– Etc,..
![Page 11: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/11.jpg)
QIAGEN NGS panel
• Tumor Actionable Mutations panel V2– BRAF, EGFR, IDH1, IDH2, KIT, KRAS, NRAS,
PDGFRA (20 ng DNA)• Clinically relevant tumor panel V2
– AKT1, IDH2, ALK, KIT, AR, KRAS, BRAF, MAP2K1, CTNNB1, MET, DDR2, NRAS, EGFR, PDGFRA, ERBB2, PIK3CA, FGFR3, PTEN, GNA11, RET, GNAQ, STK11, IDH1, TP53 (40 ng)
BIOINFORMATICS
![Page 12: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/12.jpg)
Tumor Actionable Mutations panel V2
![Page 13: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/13.jpg)
Tumor Actionable Mutations panel V2
![Page 14: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/14.jpg)
Mutation testing in blood
Liquid biopsy
• Free DNA: plasma– Diagnostic– Prognostic– Predictive
• Response to targeted therapy• Early relapse
![Page 15: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/15.jpg)
Liquid biopsyin practice
• Working from plasma has become realistic thanks to tubes delaying cell lysis (PAXGENE)
• Sensitivity: around 70%; BEAMing Digital PCR technology: over 90%?
• Targeted: single genes• Commercial kits available
– therascreen EGFR Plasma RGQ PCR Kit exon 19 deletions and exons 20 and 21 substitutions (T790M and L858R respectively); IVD
![Page 16: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/16.jpg)
Liquid biopsyin practice
• Surrogate to tissue testing• Detecting resistance mutation (T790M) in patients under
anti EGFR therapy• Monitoring response to treatment (assuming mutation
was detected in blood at diagnosis) and diagnosing early relapses: ?to switch to second generation of tki
![Page 17: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/17.jpg)
Microscope based tests
• IHC• FISH• Digital Pathology
![Page 18: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/18.jpg)
“Molecular IHC”
• Antibody set up for accurate assessment of level of expression to be clinically relevant– ALK – MET– BRAF– PDL1
FDA inspired; locked protocols
Validated against clinical significance
![Page 19: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/19.jpg)
Fluorescent In Situ HybridizationFISH
• Very accurate• Still extensively used in trials (ALK, ROS,Her2)
• BUT– Labour intensive and expensive – Dark room…
• To be “modernised”– Scanning for digitalisation of the images– Applying algorithms for interpretation
![Page 20: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/20.jpg)
Digital pathology
![Page 21: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/21.jpg)
FISH/IHC interpretation from digitalised slides
• Fluorescent sections scanned• Areas of interest selected on screen• Software calculates rate of positivity with detailed report
on number of cells examined, ratio normal/abnormal etc,..
![Page 22: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/22.jpg)
Anti PD1 therapy
![Page 23: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/23.jpg)
Anti PD1 therapy
![Page 24: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/24.jpg)
PDL1 IHC
![Page 25: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/25.jpg)
Perspective Digital pathology
![Page 26: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/26.jpg)
Tumour infiltrating lymphocytes
• CD3/CD45RO• CD3/CD8 • CD8/CD45RO• More
![Page 27: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/27.jpg)
Immunoscore
![Page 28: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/28.jpg)
Immunoscore
![Page 29: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/29.jpg)
Immunoscore
![Page 30: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/30.jpg)
Predictive markers to response to non targeted chemotherapy
![Page 31: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/31.jpg)
Platinum based drugs and ERCC1
![Page 32: Molecular Testing of lung cancer in routine practice Philippe Taniere Histopathology/Molecular Pathology, Queen Elizabeth Hospital, Birmingham.](https://reader035.fdocuments.us/reader035/viewer/2022062320/56649d775503460f94a5a0fc/html5/thumbnails/32.jpg)
Molecular Diagnostic ServiceDNA analysis in FFPE specimensSingle mutation testingNGS panelsMethylation assays
DNA analysis in blood
ImmunohistochemistrySingle test, IVD protocolsQuantification on digitalised slides
F
I
S
H
P
a
rti
a
l
a
u
t
o
m
a
ti
o
n
o
f
i
n
t
e
r
p
r
e
t
a
ti
o
n
o
n
d
i
g
it
a
li
s
e
d
s
li
d
e
s
Optimal molecular diagnostic service